Bimekizumab

Bimekizumab is a monoclonal antibody used in the treatment of psoriasis and other inflammatory conditions. It is marketed under the trade name Bimzelx. Bimekizumab works by selectively inhibiting the activity of interleukin-17A (IL-17A) and interleukin-17F (IL-17F), which are cytokines involved in inflammatory processes.

Mechanism of Action

Bimekizumab is a biologic therapy that targets and neutralizes IL-17A and IL-17F. These cytokines are part of the interleukin-17 family, which plays a crucial role in the pathogenesis of autoimmune diseases such as psoriasis. By inhibiting these cytokines, bimekizumab reduces inflammation and the symptoms associated with psoriasis.

Clinical Use

Bimekizumab is primarily used for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is administered via subcutaneous injection.

Administration

The recommended dosage of bimekizumab is an initial dose followed by maintenance doses at regular intervals. The specific dosing schedule may vary based on the patient's response and the prescribing physician's recommendations.

Side Effects

Common side effects of bimekizumab include upper respiratory tract infections, headache, and injection site reactions. Serious side effects may include increased risk of infections, such as tuberculosis, and hypersensitivity reactions.

Contraindications

Bimekizumab is contraindicated in patients with known hypersensitivity to the drug or any of its components. It should be used with caution in patients with a history of chronic infections or those who are immunocompromised.

Related Pages

• Psoriasis
• Monoclonal antibody therapy
• Interleukin-17
• Autoimmune disease